Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
VectorBuilder and Lir Therapeutics are combining AAV capsid engineering, AI-guided design and translational development capabilities as they seek to narrow the gap between promising gene therapy vectors and clinically viable candidates. Representative image.
Pharma & Biotech

What the VectorBuilder and Lir Therapeutics alliance means for next-generation gene therapy vectors

VectorBuilder and Lir Therapeutics are linking AI-guided AAV capsid design with translational development to tackle gene therapy delivery barriers.

Read More
A representative image illustrating Regeneron Pharmaceuticals’ Pasatru approval as the FDA clears the new fibrodysplasia ossificans progressiva treatment after Phase 3 data showed a 90% reduction in new heterotopic ossification lesions.
Pharma & Biotech

FDA clears monthly Pasatru after Phase 3 data show sharp drop in abnormal bone formation

FDA approves Regeneron’s Pasatru after Phase 3 data showed a 90% reduction in new FOP bone lesions. See what the new therapy means.

Read More
A representative image illustrating Teva Pharmaceutical Industries’ ecopipam program as the FDA grants Priority Review for the investigational pediatric Tourette syndrome treatment following positive Phase 3 relapse-prevention data.
Pharma & Biotech

Teva’s ecopipam reaches FDA Priority Review after positive Phase 3 Tourette data

FDA grants Priority Review to Teva’s ecopipam after Phase 3 data showed a 53% lower Tourette relapse risk. See what the 2027 decision could mean.

Read More
A representative image illustrating Humacyte, Inc.’s ATEV hemodialysis access program as peer-reviewed Phase 3 V007 data strengthen the company’s planned FDA filing for a potential dialysis indication.
Medical Devices & Diagnostics

ATEV beats AV fistula in Phase 3 dialysis trial as Humacyte prepares FDA filing

Humacyte’s ATEV beats AV fistula in Phase 3 dialysis access testing as peer-reviewed V007 data strengthen its planned 2026 FDA filing.

Read More
plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.
Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

plated Skin Science takes platelet-derived exosomes beyond facial care with its $338 BODY Serum, backed by new 12-week cosmetic study data.

Read More
Genetix Biotherapeutics’ partnership with the National Football League Alumni Association highlights efforts to expand sickle cell disease awareness and improve understanding of gene therapy treatment options, including LYFGENIA. Representative image.
Pharma & Biotech

Genetix Biotherapeutics targets sickle cell treatment awareness with NFL Alumni partnership

Genetix Biotherapeutics and NFL Alumni are targeting the awareness and access gap that still limits sickle cell gene therapy adoption.

Read More
Cytovance Biologics is expanding its biologics development model with standalone analytical services covering method development, validation, GMP testing and stability programs without requiring a manufacturing contract. Representative image.
Pharma & Biotech

Cytovance widens biologics development offering after cell line and perfusion expansions

Cytovance Biologics opens GMP and non-GMP analytical testing without manufacturing contracts, widening its biologics development model.

Read More
Vero Bioscience is combining Stanford University’s proteomic organ-aging and Cell Clock technologies to develop OrganAge, a blood-based platform designed to assess biological aging across organs and cell types as the company moves toward broader consumer availability in 2027. Representative image.
Medical Devices & Diagnostics

Can one blood test reveal which cells are aging fastest? Vero brings Stanford Cell Clock into OrganAge

Vero adds Stanford Cell Clock technology to OrganAge ahead of a 2027 rollout, while clinical validation remains the key commercial test.

Read More
Gemelli Biotech’s IBS-Smart and Trio-Smart testing was linked to lower use of selected diagnostic procedures and lower captured diagnostic costs in a real-world irritable bowel syndrome study. Representative image.
Medical Devices & Diagnostics

Gemelli Biotech IBS-Smart study finds lower diagnostic costs in patients with suspected IBS

Gemelli Biotech’s IBS-Smart and Trio-Smart were linked to lower captured diagnostic costs in a 219-patient IBS study, but causality remains unproven.

Read More
Genetic testing utilization management moves to Zyter as InformedDNA concentrates its 2026 strategy around the DNAimpact precision health platform. Representative image.
Medical Devices & Diagnostics

InformedDNA has now divested two businesses in 2026. Why is everything pointing toward DNAimpact?

InformedDNA divests its genetic testing utilization management unit to Zyter, sharpening its DNAimpact precision health strategy after two 2026 deals.

Read More